SPOTLIGHT: Abbott and Caprion Proteomics extend partnership


Abbott and Caprion Proteomics, a general partnership wholly owned by Thallion Pharmaceuticals have extended their discovery partnership to investigate viable human therapeutic antibody targets for oncology using their CellCarta technology platform. Release